{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:40:11Z","timestamp":1786977611770,"version":"build-2736575974"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":613,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The safety and effectiveness of the MitraClip device to treat functional mitral regurgitation (FMR) has been tested in previous clinical trials yielding somewhat heterogeneous results in heart failure (HF) patients. Over time, the MitraClip device system has been modified and clinical practice evolved to consider also less severely diseased HF patients with FMR for this therapeutic option. The RESHAPE-HF2 trial aims to assess the safety and effectiveness of the MitraClip device system on top of medical therapy considered optimal in the treatment of clinically significant FMR in symptomatic patients with chronic HF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The RESHAPE-HF2 is an investigator-initiated, prospective, randomized, parallel-controlled, multicentre trial designed to evaluate the use of the MitraClip device (used in the most up-to-date version as available at sites) plus optimal standard of care therapy (device group) compared to optimal standard of care therapy alone (control group). Eligible subjects have signs and symptoms of HF (New York Heart Association [NYHA] class II\u2013IV despite optimal therapy), and have moderate-to-severe or severe FMR, as confirmed by a central echocardiography core laboratory; have an ejection fraction between \u226520% and \u226450% (initially 15\u201335% for NYHA class II patients, and 15\u201345% for NYHA class III\/IV patients); have been adequately treated per applicable standards, and have received appropriate revascularization and cardiac resynchronization therapy, if eligible; had a HF hospitalization or elevated natriuretic peptides (B-type natriuretic peptide [BNP] \u2265300\u2009pg\/ml or N-terminal proBNP \u22651000\u2009pg\/ml) in the last 90\u2009days; and in whom isolated mitral valve surgery is not a recommended treatment option. The trial has three primary endpoints, which are these: (i) the composite rate of total (first and recurrent) HF hospitalizations and cardiovascular death during 24 months of follow-up, (ii) the rate of total (i.e. first and recurrent) HF hospitalizations within 24\u2009months, and (iii) the change from baseline to 12\u2009months in the Kansas City Cardiomyopathy Questionnaire overall score. The three primary endpoints will be analysed using the Hochberg procedure to control the familywise type I error rate across the three hypotheses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The RESHAPE-HF2 trial will provide sound evidence on the MitraClip device and its effects in HF patients with FMR. The recruitment was recently completed with 506 randomized patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.3247","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T23:19:20Z","timestamp":1713914360000},"page":"984-993","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Randomized Investigation of the MitraClip Device in Heart Failure: Design and Rationale of the RESHAPE-HF2 Trial Design"],"prefix":"10.1093","volume":"26","author":[{"given":"Stefan D.","family":"Anker","sequence":"first","affiliation":[{"name":"Department of Cardiology (CVK) of German Heart Center Charit\u00e9, German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Friede","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, University Medical Center G\u00f6ttingen, German Centre for Cardiovascular Research (DZHK), partner site G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph Stephan","family":"von Bardeleben","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Kardiologie, Johannes-Gutenberg-Universit\u00e4t , Mainz ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Mississippi Medical Center , Jackson, MS ,","place":["USA"]},{"name":"Baylor Scott and White Research Institute , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaneez","family":"Fatima","sequence":"additional","affiliation":[{"name":"Department of Research, Baylor Scott and White Research Institute , Dallas, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Diek","sequence":"additional","affiliation":[{"name":"Department of Cardiology (CVK) of German Heart Center Charit\u00e9, German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charit\u00e9 Universit\u00e4tsmedizin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Heinrich","sequence":"additional","affiliation":[{"name":"Clinical Trial Unit, University Medical Center G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Hasenfu\u00df","sequence":"additional","affiliation":[{"name":"Heart Research Center G\u00f6ttingen, Clinic for Cardiology and Pneumology, University Medical Center G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Schillinger","sequence":"additional","affiliation":[{"name":"Heart Center, Department of Cardiology, Georg-August-University G\u00f6ttingen , G\u00f6ttingen ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Institute of Heart Diseases, Wroclaw Medical University , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,23]]},"reference":[{"key":"2026010913075477900_ejhf3247-bib-0001","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1388-9842(02)00116-2","article-title":"Annual rates of admission and seasonal variations in hospitalizations for heart failure","volume":"4","author":"Mart\u00ednez-Sell\u00e9s","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"2026010913075477900_ejhf3247-bib-0002","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0735-1097(01)01605-9","article-title":"Quantitation of functional mitral regurgitation during bicycle exercise in patients with heart failure","volume":"38","author":"Lebrun","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026010913075477900_ejhf3247-bib-0003","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0300-8932(10)70185-8","article-title":"Progress in the treatment of severe mitral regurgitation","volume":"63","author":"Michelena","year":"2010","journal-title":"Rev Esp Cardiol"},{"key":"2026010913075477900_ejhf3247-bib-0004","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/CRD.0b013e3181e8e648","article-title":"Functional mitral regurgitation","volume":"18","author":"Schmitto","year":"2010","journal-title":"Cardiol Rev"},{"key":"2026010913075477900_ejhf3247-bib-0005","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jacc.2017.03.011","article-title":"2017 AHA\/ACC Focused Update of the 2014 AHA\/ACC Guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"70","author":"Nishimura","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026010913075477900_ejhf3247-bib-0006","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa013168","article-title":"Cardiac resynchronization in chronic heart failure","volume":"346","author":"Abraham","year":"2002","journal-title":"N Engl J Med"},{"key":"2026010913075477900_ejhf3247-bib-0007","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/ejcts\/ezs078","article-title":"Long-term results of mitral repair for functional mitral regurgitation in idiopathic dilated cardiomyopathy","volume":"42","author":"De Bonis","year":"2012","journal-title":"Eur J Cardiothorac Surg"},{"key":"2026010913075477900_ejhf3247-bib-0008","doi-asserted-by":"crossref","first-page":"I573","DOI":"10.1161\/CIRCULATIONAHA.105.001230","article-title":"Impact of moderate functional mitral insufficiency in patients undergoing surgical revascularization","volume":"114","author":"Grossi","year":"2006","journal-title":"Circulation"},{"key":"2026010913075477900_ejhf3247-bib-0009","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/01.CIR.0000079169.15862.13","article-title":"Outcomes and long-term survival for patients undergoing mitral valve repair versus replacement: Effect of age and concomitant coronary artery bypass grafting","volume":"108","author":"Thourani","year":"2003","journal-title":"Circulation"},{"key":"2026010913075477900_ejhf3247-bib-0010","first-page":"427","article-title":"Results following valve replacement for ischemic mitral regurgitation","volume":"17","author":"Bouchard","year":"2001","journal-title":"Can J Cardiol"},{"key":"2026010913075477900_ejhf3247-bib-0011","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"2026010913075477900_ejhf3247-bib-0012","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.jacc.2013.02.094","article-title":"Percutaneous valve interventions in real world: Early and 1-year results from the ACCESS-EU, a prospective, multicenter, nonrandomised post-approval study of the MitraClip therapy in Europe","volume":"62","author":"Maisano","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026010913075477900_ejhf3247-bib-0013","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.jacc.2011.06.061","article-title":"Correction of mitral regurgitation in non-responders to cardiac resynchronization therapy by MitraClip improves symptoms and promotes reverse remodelling","volume":"58","author":"Auricchio","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026010913075477900_ejhf3247-bib-0014","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa1805374","article-title":"Percutaneous repair or medical treatment for secondary mitral regurgitation","volume":"379","author":"Obadia","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913075477900_ejhf3247-bib-0015","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913075477900_ejhf3247-bib-0016","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ejechocard\/jeq031","article-title":"European Association of Echocardiography recommendations for the assessment of valvular regurgitation. Part 2: Mitral and tricuspid regurgitation (native valve disease)","volume":"11","author":"Lancellotti","year":"2010","journal-title":"Eur J Echocardiogr"},{"key":"2026010913075477900_ejhf3247-bib-0017","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejheart.2008.01.009","article-title":"Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients","volume":"10","author":"Pfister","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026010913075477900_ejhf3247-bib-0018","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/eurheartj\/ehp210","article-title":"Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: An analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study","volume":"30","author":"Berger","year":"2009","journal-title":"Eur Heart J"},{"key":"2026010913075477900_ejhf3247-bib-0019","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ejheart.2007.07.010","article-title":"Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: Results from the Carvedilol or Metoprolol European Trial (COMET) trial","volume":"9","author":"Olsson","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026010913075477900_ejhf3247-bib-0020","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/eurheartj\/ehi555","article-title":"Predictors of mortality and morbidity in patients with chronic heart failure","volume":"27","author":"Pocock","year":"2006","journal-title":"Eur Heart J"},{"key":"2026010913075477900_ejhf3247-bib-0021","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","article-title":"Burden of valvular heart diseases: A population-based study","volume":"368","author":"Nkomo","year":"2006","journal-title":"Lancet"},{"key":"2026010913075477900_ejhf3247-bib-0022","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1161\/01.CIR.103.13.1759","article-title":"Ischemic mitral regurgitation: Long-term outcome and prognostic implications with quantitative doppler assessment","volume":"103","author":"Grigioni","year":"2001","journal-title":"Circulation"},{"key":"2026010913075477900_ejhf3247-bib-0023","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1067\/mhj.2002.123575","article-title":"Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction","volume":"144","author":"Koelling","year":"2002","journal-title":"Am Heart J"},{"key":"2026010913075477900_ejhf3247-bib-0024","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0002-9149(02)03172-7","article-title":"Prevalence and severity of mitral regurgitation in chronic systolic heart failure","volume":"91","author":"Robbins","year":"2003","journal-title":"Am J Cardiol"},{"key":"2026010913075477900_ejhf3247-bib-0025","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9149(02)03301-5","article-title":"Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure","volume":"91","author":"Trichon","year":"2003","journal-title":"Am J Cardiol"},{"key":"2026010913075477900_ejhf3247-bib-0026","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1136\/hrt.2011.225789","article-title":"Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and nonischaemic dilated cardiomyopathy","volume":"97","author":"Rossi","year":"2011","journal-title":"Heart"},{"key":"2026010913075477900_ejhf3247-bib-0027","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/hrt.2008.160010","article-title":"Predicting outcome after valve replacement","volume":"96","author":"Rimington","year":"2010","journal-title":"Heart"},{"key":"2026010913075477900_ejhf3247-bib-0028","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/heart.83.6.645","article-title":"Health related quality of life and psychological wellbeing in patients with dilated cardiomyopathy","volume":"83","author":"Steptoe","year":"2000","journal-title":"Heart"},{"key":"2026010913075477900_ejhf3247-bib-0029","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N Engl J Med"},{"key":"2026010913075477900_ejhf3247-bib-0030","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1009355","article-title":"Percutaneous repair or surgery for mitral regurgitation","volume":"364","author":"Feldman","year":"2011","journal-title":"N Engl J Med"},{"key":"2026010913075477900_ejhf3247-bib-0031","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacc.2013.04.030","article-title":"4 year results of the randomised controlled trial of percutaneous repair vs surgery for mitral regurgitation","volume":"62","author":"Mauri","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026010913075477900_ejhf3247-bib-0032","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00059-013-3858-3","article-title":"TRAMI (Transcatheter Mitral Valve Interventions) register. The German mitral register","volume":"38","author":"Schillinger","year":"2013","journal-title":"Herz"},{"key":"2026010913075477900_ejhf3247-bib-0033","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa2300213","article-title":"Five-year follow-up after transcatheter repair of secondary mitral regurgitation","volume":"388","author":"Stone","year":"2023","journal-title":"N Engl J Med"},{"key":"2026010913075477900_ejhf3247-bib-0034","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/CIRCULATIONAHA.118.037077","article-title":"Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation","volume":"139","author":"Khang","year":"2019","journal-title":"Circulation"},{"key":"2026010913075477900_ejhf3247-bib-0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4081\/cardio.2023.6","article-title":"Evolving targets for heart failure: The journey so far","volume":"1","author":"Rosano","year":"2023","journal-title":"Global Cardiol"},{"key":"2026010913075477900_ejhf3247-bib-0036","doi-asserted-by":"crossref","first-page":"55","DOI":"10.4081\/cardio.2023.2","article-title":"SGLT2 inhibitors and risk reduction for mortality in high-risk patients: A meta-analysis of randomized controlled trials","volume":"1","author":"Siddiqi","year":"2023","journal-title":"Global Cardiol"},{"key":"2026010913075477900_ejhf3247-bib-0037","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0002-8703(00)90036-X","article-title":"Beta-blockade therapy in chronic heart failure: Diastolic function and mitral regurgitation improvement by carvedilol","volume":"139","author":"Capomolla","year":"2000","journal-title":"Am Heart J"},{"key":"2026010913075477900_ejhf3247-bib-0038","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/hrt.72.1.63","article-title":"Effect of captopril on functional mitral regurgitation in dilated heart failure: A randomised double blind placebo controlled trial","volume":"72","author":"Seneviratne","year":"1994","journal-title":"Br Heart J"},{"key":"2026010913075477900_ejhf3247-bib-0039","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"2026010913075477900_ejhf3247-bib-0040","article-title":"Clinical trial design, endpoints and regulatory considerations in heart failure","author":"Rosano","journal-title":"Global Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/4\/984\/65514299\/eurjhf_26_4_984.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/26\/4\/984\/65514299\/eurjhf_26_4_984.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:09:48Z","timestamp":1767982188000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/26\/4\/984\/8328882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,23]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.3247","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4]]},"published":{"date-parts":[[2024,4,1]]},"assertion":[{"value":"2024-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-23","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}